Skip to main
IMMP

Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd (IMMP) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Immutep is positioning itself as a leader in the LAG-3 immunotherapy space with a strong pipeline and strategic collaborations. The company's financials are strong, with a cash balance of $60 million and a debt-free balance sheet. Immutep has also secured funding from government grants and has collaborations with major pharmaceutical companies, providing additional financial support for its research and development efforts. Overall, Immutep has a promising outlook as a potential leader in LAG-3 related immunotherapies, with a strong drug candidate, experienced leadership team, and solid financial foundation.

Bears say

Immutep is facing significant hurdles in its Phase three clinical trials, as KOLs are skeptical about the durability and OS trajectory of efti and note the concerns surrounding larger, randomized NSCLC datasets. Furthermore, while adenocarcinoma is the most common type of NSCLC, it develops in the smaller airways and is usually found in areas of chronic inflammation, leading to doubts about efti's effectiveness in treating this subtype. Additionally, the company is facing competition in the rapidly evolving field of targeted therapies, with only one other company exploring a comparable LAG-3 agonist approach, and a majority of companies focused on LAG-3 antagonists. With a risky and capital-intensive drug development process, Immutep's current Phase three trial for NSCLC poses significant binary outcome risk.

Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immutep Ltd (IMMP) Forecast

Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.

According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immutep Ltd (IMMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.